MaaT Pharma, SA
5 Place Charles
About MaaT Pharma, SAMaaT Pharma (Microbiota as a Therapy) is a French biotech start-up, created at the end of 2014, to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis. Funded jointly by a team which brings together world-class medical-scientific and entrepreneurial skills, MaaT Pharma has the ambition of becoming a leader in microbiome protection and the treatment of dysbiosis.
Co-Founder and CEO: Herve´ Affagard
Co-Founder and Non Executive President of the Board: Dr Pierre Belichard
Co-Founder: Mr. Joël Doré
Co-Founder: Mr. Pierre Rimbaud
Please click here for Auspherix's job opportunities.
Please click here for MaaT Pharma's pipeline.
58 articles with MaaT Pharma, SA
MaaT Pharma to Present Initial Results with its Lead Microbiota Biotherapeutic in Intestinal GvHD at 61st American Society of Hematology (ASH) Annual Meeting
Pooled-donor full ecosystem microbiota biotherapeutic reported safe in eight patients treated
9/13/2019Biotech and pharma companies strengthen their leadership teams with new appointments.
MaaT Pharma Expands Executive Team to Strengthen Corporate Development and Accelerate Expansion of Microbiome Data Science Platform, GutPrint
MaaT Pharma announced the appointment of Jean-Marc Renard, MS, MBA, as Chief Business Officer and Emmanuel Prestat, PhD as Computational Biology Manager.
MaaT Pharma Completes Third Positive DSMB Assessment Setting High Safety Standard for Human Intestinal Microbiome Whole Ecosystem-Based Therapeutics
Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute GvHD with no safety concerns occurring within the study
5/23/2019Biopharma companies from across Europe share pipeline and strategy updates.
MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform
MaaT Pharma announced that the Institut National de la Propriété Industrielle (INPI), the French Patent Office, has issued three new patents to the company covering its sample collection device and the overall processes associated with obtaining, processing, storing and administering human gut samples, ensuring that the highest quality of microbiota is present in MaaT Pharma’s biologic drugs.
Pharma and biotech companies from Asia to Europe provide updates on business and clinical activities.
MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute GvHD
Independent Data Safety Monitoring Board (DSMB) recommends HERACLES trial to continue without modification
MaaT Pharma Announces Positive DSMB Safety Review and Continuation of its Phase II HERACLES Study in Acute GvHD
Independent Data Safety Monitoring Board (DSMB) recommends to continue HERACLES study without modification
MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients at the ASH 2018 Annual Meeting
MaaT Pharma announced today the results from its ODYSSEE (NCT02928523) Phase 1b/2a clinical trial demonstrating that the Company’s proprietary MaaT Microbiome Restoration Biotherapeutic (MMRB) therapeutic is able to restore a functional microbiome in acute myeloid leukemia (AML) patients after having undergone intensive chemotherapy and multiple courses of antibiotics.
MaaT Pharma to Present Positive Results from Phase 1b/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting
MaaT Pharma announced today that the company will present a poster summarizing the complete results from its ODYSSEE Phase 1b/2a trial (NCT02928523).
MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD
Microbiome restoration biological drug product to be tested for safety and overall survival impact in patients with acute Graft-versus-Host-Disease
MaaT Pharma Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic at 2018 EMBO Symposium on the Human Microbiome
Results from in silico analysis using MaaT Pharma’s data analysis platform, GutPrint, demonstrate therapeutic rationale and manufacturing capabilities of developing a high diversity biological drug product
MaaT Pharma receives world-wide exclusive license to technology co-developed with hematology and gastroenterology departments of Saint-Antoine Hospital, Paris
A Major Step In The Restoration Of Gut Microbiota: MaaT Pharma And Biocodex To Industrialize FMT & Develop An Oral Formulation
MaaT Pharma And BIOASTER Enter In Collaboration To Investigate The Potentiality To Expand Fecal Microbiota In Vitro Under GMP Conditions For Therapeutic Use
MaaT Pharma Announces First Positive DSMB Safety Review And Continuation Of Its Phase 1b ODYSSEE Study